Pressure overload-induced right ventricular failure is associated with re-expression of Myocardial Tenascin-C and Elevated Plasma Tenascin-C Levels

Cellular Physiology and Biochemistry

Volumn 24, Issue 3-4, 2009, Pages 201-210

  Hessel, Marleen ^a   Steendijk, Paul ^a   Den Adel, Brigit ^a   Schutte, Cindy ^a   Van Der Laarse, Arnoud ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Integrins; Matrix metalloproteinases; Monocrotaline; Right ventricular failure; Right ventricular remodeling; Tenascin C

Indexed keywords

ALPHA6 INTEGRIN; BETA1 INTEGRIN; GELATINASE A; GELATINASE B; MONOCROTALINE; SODIUM CHLORIDE; TENASCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEART DILATATION; HEART LEFT VENTRICLE; HEART MUSCLE; HEART RIGHT VENTRICLE; HEART RIGHT VENTRICLE EJECTION FRACTION; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE OVERLOAD; HEART RIGHT VENTRICLE VOLUME; HEART VENTRICLE REMODELING; HEART VENTRICLE SEPTUM; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RAT; UPREGULATION;

RATTUS;

EID: 68349128559     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000233246     Document Type: Article

References (40)

1. Jones PL, Jones FS: Tenascin-C in development and disease: gene regulation and cell function. Matrix Biol 2000;19:581-596.
2. Imanaka-Yoshida K, Hiroe M, Nishikawa T, Ishiyama S, Shimojo T, Ohta Y, Sakakura T, Yoshida T: Tenascin-C modulates adhesion of cardiomyocytes to extracellular matrix during tissue remodeling after myocardial infarction. Lab Invest 2001;81:1015-1024.
3. Imanaka-Yoshida K, Hiroe M, Yasutomi Y, Toyozaki T, Tsuchiya T, Noda N, Maki T, Nishikawa T, Sakakura T, Yoshida T: Tenascin-C is a useful marker for disease activity in myocarditis. J Pathol 2002;197:388-394.
4. Tamura A, Kusachi S, Nogami K, Yamanishi A, Kajikawa Y, Hirohata S, Tsuji T: Tenascin expression in endomyocardial biopsy specimens in patients with dilated cardiomyopathy: distribution along margin of fibrotic lesions. Heart 1996;75:291-294.
5. Hessel MH, Bleeker GB, Bax JJ, Henneman MM, den Adel B, Klok M, Schalij MJ, Atsma DE, van der Laarse A: Reverse ventricular remodelling after cardiac resynchronization therapy is associated with a reduction in serum tenascin-C and plasma matrix metalloproteinase-9 levels. Eur J Heart Fail 2007;9(10):1058-63.
6. Kinugawa S, Tsutsui H, Hayashidani S, Ide T, Suematsu N, Satoh S, Utsumi H, Takeshita A: Treatment with dimethylthiourea prevents left ventricular remodeling and failure after experimental myocardial infarction in mice: role of oxidative stress. Circ Res 2000;87:392-398.
7. Terasaki F, Okamoto H, Onishi K, Sato A, Shimomura H, Tsukada B, Imanaka-Yoshida K, Hiroe M, Yoshida T, Kitaura Y, Kitabatake A: Higher serum tenascin-C levels reflect the severity of heart failure, left ventricular dysfunction and remodeling in patients with dilated cardiomyopathy. Circ J 2007;71:327-330.
8. Chiquet M: Regulation of extracellular matrix gene expression by mechanical stress. Matrix Biol 1999;18:417-426.
9. Jarvinen TA, Jozsa L, Kannus P, Jarvinen TL, Hurme T, Kvist M, Pelto-Huikko M, Kalimo H, Jarvinen M: Mechanical loading regulates the expression of tenascin-C in the myotendinous junction and tendon but does not induce de novo synthesis in the skeletal muscle. J Cell Sci 2003;116:857-866.
10. Yamamoto K, Dang QN, Kennedy SP, Osathanondh R, Kelly RA, Lee RT: Induction of tenascin-C in cardiac myocytes by mechanical deformation. Role of reactive oxygen species. J Biol Chem 1999;274:21840-21846.
11. Rettig WJ, Erickson HP, Albino AP, Garin-Chesa P: Induction of human tenascin (neuronectin) by growth factors and cytokines: cell type-specific signals and signalling pathways. J Cell Sci 1994;107:487-497.
12. Chiquet M, Sarasa-Renedo A, Tunc-Civelek V: Induction of tenascin-C by cyclic tensile strain versus growth factors: distinct contributions by Rho/ROCK and MAPK signaling pathways. Biochim Biophys Acta 2004;1693:193-204.
13. Imanaka-Yoshida K, Hiroe M, Yoshida T: Interaction between cell and extracellular matrix in heart disease: multiple roles of tenascin-C in tissue remodeling. Histol Histopathol 2004;19:517-525.
14. Chiquet-Ehrismann R, Matsuoka Y, Hofer U, Spring J, Bernasconi C, Chiquet M: Tenascin variants: differential binding to fibronectin and distinct distribution in cell cultures and tissues. Cell Regul 1991;2:927-938.
15. Barnea G, Grumet M, Milev P, Silvennoinen O, Levy JB, Sap J, Schlessinger J: Receptor tyrosine phosphatase beta is expressed in the form of proteoglycan and binds to the extracellular matrix protein tenascin. J Biol Chem 1994;269:14349-14352.
16. Lightner VA, Erickson HP: Binding of hexabrachion (tenascin) to the extracellular matrix and substratum and its effect on cell adhesion. J Cell Sci 1990;95:263-277.
17. Jones FS, Jones PL: The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling. Dev Dyn 2000;218:235-259.
18. Valdivia E, Lalich JJ, Hayashi Y, Sonnad J: Alterations in pulmonary alveoli after a single injection of monocrotaline. Arch Pathol 1967;84:64-76.
19. Hislop A, Reid L: Arterial changes in Crotalaria spectabilis-induced pulmonary hypertension in rats. Br J Exp Pathol 1974;55:153-163.
20. Hessel MH, Steendijk P, den Adel B, Schutte CI, van der Laarse A: Characterization of right ventricular function after monocrotaline-induced pulmonary hypertension in the intact rat. Am J Physiol Heart Circ Physiol 2006;291(5):H2424-30.
21. Baan J, van der Velde ET, de Bruin HG, Smeenk GJ, Koops J, van Dijk AD, Temmerman D, Senden J, Buis B: Continuous measurement of left ventricular volume in animals and humans by conductance catheter. Circulation 1984;70:812-823.
22. Siri A, Knauper V, Veirana N, Caocci F, Murphy G, Zardi L: Different susceptibility of small and large human tenascin-C isoforms to degradation by matrix metalloproteinases. J Biol Chem 1995;270:8650-8654.
23. Boerma M, van der Wees CG, Vrieling H, Svensson JP, Wondergem J, van der Laarse A, Mullenders LH, van Zeeland AA: Microarray analysis of gene expression profiles of cardiac myocytes and fibroblasts after mechanical stress, ionising or ultraviolet radiation. BMC Genomics 2005;6:6.
24. Maier S, Lutz R, Gelman L, Sarasa-Renedo A, Schenk S, Grashoff C, Chiquet M: Tenascin-C induction by cyclic strain requires integrin-linked kinase. Biochim Biophys Acta 2008;1783:1150-1162.
25. Sarasa-Renedo A, Tunc-Civelek V, Chiquet M: Role of RhoA/ROCKdependent actin contractility in the induction of tenascin-C by cyclic tensile strain. Exp Cell Res 2006;312:1361-1370.
26. Schott P, Singer SS, Kogler H, Neddermeier D, Leineweber K, Brodde OE, Regitz-Zagrosek V, Schmidt B, Dihazi H, Hasenfuss G: Pressure overload and neurohumoral activation differentially affect the myocardial proteome. Proteomics 2005;5:1372-1381.
27. Latijnhouwers MA, Pfundt R, de Jongh GJ, Schalkwijk J: Tenascin-C expression in human epidermal keratinocytes is regulated by inflammatory cytokines and a stress response pathway. Matrix Biol 1998;17:305-316.
28. Mackie EJ, Scott-Burden T, Hahn AW, Kern F, Bernhardt J, Regenass S, Weller A, Buhler FR: Expression of tenascin by vascular smooth muscle cells. Alterations in hypertensive rats and stimulation by angiotensin II. Am J Pathol 1992;141:377-388.
29. Lourenco AP, Roncon-Albuquerque R, Jr., Bras-Silva C, Faria B, Wieland J, Henriques-Coelho T, Correia-Pinto J, Leite-Moreira AF: Myocardial dysfunction and neurohumoral activation without remodeling in left ventricle of monocrotaline-induced pulmonary hypertensive rats. Am J Physiol Heart Circ Physiol 2006;291:H1587-1594.
30. Tamaoki M, Imanaka-Yoshida K, Yokoyama K, Nishioka T, Inada H, Hiroe M, Sakakura T, Yoshida T: Tenascin-C regulates recruitment of myofibroblasts during tissue repair after myocardial injury. Am J Pathol 2005;167:71-80.
31. Morimoto S, Imanaka-Yoshida K, Hiramitsu S, Kato S, Ohtsuki M, Uemura A, Kato Y, Nishikawa T, Toyozaki T, Hishida H, Yoshida T, Hiroe M: Diagnostic utility of tenascin-C for evaluation of the activity of human acute myocarditis. J Pathol 2005;205:460-467.
32. Danowski BA, Imanaka-Yoshida K, Sanger JM, Sanger JW: Costameres are sites of force transmission to the substratum in adult rat cardiomyocytes. J Cell Biol 1992;118:1411-1420.
33. Imanaka-Yoshida K, Enomoto-Iwamoto M, Yoshida T, Sakakura T: Vinculin, Talin, Integrin alpha6beta1 and laminin can serve as components of attachment complex mediating contraction force transmission from cardiomyocytes to extracellular matrix. Cell Motil Cytoskeleton 1999;42:1-11.
34. Yokosaki Y, Monis H, Chen J, Sheppard D: Differential effects of the integrins alpha9beta1, alphavbeta3, and alphavbeta6 on cell proliferative responses to tenascin. Roles of the beta subunit extracellular and cytoplasmic domains. J Biol Chem 1996;271:24144-24150.
35. Nishikawa N, Yamamoto K, Sakata Y, Mano T, Yoshida J, Miwa T, Takeda H, Hori M, Masuyama T: Differential activation of matrix metalloproteinases in heart failure with and without ventricular dilatation. Cardiovasc Res 2003;57:766-774.
36. Umar S, Hessel M, Steendijk P, Bax W, Schutte C, Schalij M, van der Wall E, Atsma D, van der Laarse A: Activation of signaling molecules and matrix metalloproteinases in right ventricular myocardium of rats with pulmonary hypertension. Pathol Res Pract 2007;203:863-872.
37. van den Borne SW, Cleutjens JP, Hanemaaijer R, Creemers EE, Smits JF, Daemen MJ, Blankesteijn WM: Increased matrix metalloproteinase-8 and -9 activity in patients with infarct rupture after myocardial infarction. Cardiovasc Pathol 2009;18:37-43.
38. Lindsey M, Wedin K, Brown MD, Keller C, Evans AJ, Smolen J, Burns AR, Rossen RD, Michael L, Entman M: Matrixdependent mechanism of neutrophilmediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion. Circulation 2001;103:2181-2187.
39. Aukrust P, Gullestad L, Ueland T, Damas JK, Yndestad A: Inflammatory and antiinflammatory cytokines in chronic heart failure: potential therapeutic implications. Ann Med 2005;37:74-85.
40. Torre-Amione G: Immune activation in chronic heart failure. Am J Cardiol 2005;95:3C-8C.